HDAC1, histone deacetylase 1, 3065

N. diseases: 277; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 Biomarker disease BEFREE Our data suggest that HDAC1 inhibition should be considered as a therapeutic approach to treat schizophrenia. 28533418 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 AlteredExpression disease BEFREE We used >700 well-characterized samples from patients diagnosed with schizophrenia (n = 175), major depressive disorder (n = 135), and bipolar disorder (n = 61) to measure HDAC1 and HDAC2 transcript levels by quantitative real-time PCR in dorsolateral prefrontal cortex (DLPFC) and caudate compared to control samples. 27959513 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 AlteredExpression disease BEFREE Several of the genes in this network including epigenetic factors histone deacetylase 1 (HDAC1) and death-associated protein 6 (DAXX), the GABAergic enzyme GAD65 as well as the kainate receptor (KAR) subunits GluR6 and 7 show significant changes in expression in this area in SZ. 27733539 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 Biomarker disease BEFREE To characterize the contribution of these factors to the developmental perturbation hypothesized to underlie SZ, lentiviral vectors carrying short hairpin RNA interference (shRNAi) for HDAC1 and DAXX were used. 26812044 2016
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 Biomarker disease PSYGENET Postmortem brain studies have shown that HDAC1-a lysine deacetylase with broad activity against histones and nonhistone proteins-is frequently expressed at increased levels in prefrontal cortex (PFC) of subjects diagnosed with schizophrenia and related disease. 23664640 2013
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 AlteredExpression disease BEFREE In summary, we suggest that reduced p35 expression in schizophrenia has an impact on synaptic protein expression and cognition and that these deficits can be rescued, at least in part, by the inhibition of histone deacetylase 1. 21772061 2011
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 AlteredExpression disease BEFREE The mRNA expression level of an epigenetically regulated schizophrenia candidate gene GAD67 was strongly and negatively correlated with the mRNA expression levels of HDAC1, HDAC3 and HDAC4 levels. 17961987 2008
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 AlteredExpression disease LHGDN The mRNA expression level of an epigenetically regulated schizophrenia candidate gene GAD67 was strongly and negatively correlated with the mRNA expression levels of HDAC1, HDAC3 and HDAC4 levels. 17961987 2008
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 Biomarker disease PSYGENET The mRNA expression level of an epigenetically regulated schizophrenia candidate gene GAD67 was strongly and negatively correlated with the mRNA expression levels of HDAC1, HDAC3 and HDAC4 levels. 17961987 2008
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.320 Biomarker disease CTD_human Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. 21527555 2011
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.320 AlteredExpression disease BEFREE Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. 21527555 2011
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.320 AlteredExpression disease LHGDN Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. 12579268 2003
CUI: C3463824
Disease: MYELODYSPLASTIC SYNDROME
MYELODYSPLASTIC SYNDROME 		0.310 AlteredExpression group BEFREE Apoptotic cells significantly increased in both types of MDS. mRNA and protein levels of HDAC1 and TLR2 were reduced, whereas GATA-1 was increased in both types of MDS. 28963909 2017
CUI: C3463824
Disease: MYELODYSPLASTIC SYNDROME
MYELODYSPLASTIC SYNDROME 		0.310 Biomarker group CTD_human Apoptotic cells significantly increased in both types of MDS. mRNA and protein levels of HDAC1 and TLR2 were reduced, whereas GATA-1 was increased in both types of MDS. 28963909 2017
CUI: C0269102
Disease: Endometrioma
Endometrioma 		0.310 AlteredExpression disease BEFREE Histone deacetylase-1 target mRNAs that were up-regulated by valproic acid (VPA) treatment in endometriotic cyst stromal cells (ECSCs) were identified by a global mRNA microarray technique. 23833041 2013
CUI: C0014175
Disease: Endometriosis
Endometriosis 		0.310 AlteredExpression disease BEFREE HDAC1 and HDAC2 are differentially expressed in endometriosis. 22344732 2012
CUI: C0014175
Disease: Endometriosis
Endometriosis 		0.310 Biomarker disease CTD_human Nuclear receptor, coregulator signaling, and chromatin remodeling pathways suggest involvement of the epigenome in the steroid hormone response of endometrium and abnormalities in endometriosis. 22138541 2012
CUI: C0269102
Disease: Endometrioma
Endometrioma 		0.310 Biomarker disease CTD_human Nuclear receptor, coregulator signaling, and chromatin remodeling pathways suggest involvement of the epigenome in the steroid hormone response of endometrium and abnormalities in endometriosis. 22138541 2012
CUI: C2713368
Disease: Hematopoetic Myelodysplasia
Hematopoetic Myelodysplasia 		0.300 Biomarker phenotype CTD_human Effects of arsenic disulfide on apoptosis, histone acetylation, toll like receptor 2 activation, and erythropoiesis in bone marrow mononuclear cells of myelodysplastic syndromes patients in vitro. 28963909 2017
CUI: C0525045
Disease: Mood Disorders
Mood Disorders 		0.300 Biomarker group PSYGENET These results provide evidence that selective inhibition of HDAC1 and HDAC2 in brain may provide an epigenetic-based target for developing improved treatments for mood disorders and other brain disorders with altered chromatin-mediated neuroplasticity. 23967191 2013
CUI: C0340543
Disease: Familial primary pulmonary hypertension
Familial primary pulmonary hypertension 		0.300 Biomarker disease CTD_human Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. 22711276 2012
CUI: C1969342
Disease: PULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-ASSOCIATED
PULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-ASSOCIATED 		0.300 Biomarker disease CTD_human Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. 22711276 2012
CUI: C1969343
Disease: Pulmonary Hypertension, Primary, Fenfluramine-Associated
Pulmonary Hypertension, Primary, Fenfluramine-Associated 		0.300 Biomarker disease CTD_human Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. 22711276 2012
CUI: C3203102
Disease: Idiopathic pulmonary arterial hypertension
Idiopathic pulmonary arterial hypertension 		0.300 Biomarker disease CTD_human HDAC1 and HDAC5 protein levels were elevated in lungs from human idiopathic pulmonary arterial hypertension and in lungs and right ventricles from rats exposed to hypoxia. 22711276 2012
CUI: C3714844
Disease: Pulmonary Hypertension, Primary, 1, With Hereditary Hemorrhagic Telangiectasia
Pulmonary Hypertension, Primary, 1, With Hereditary Hemorrhagic Telangiectasia 		0.300 Biomarker disease CTD_human Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. 22711276 2012